Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes
- 1 April 2018
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 78 (4) , 694-700
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Anti-tumor activity of metformin: from metabolic and epigenetic perspectivesOncotarget, 2016
- Obesity as a risk factor for malignant melanoma and non-melanoma skin cancerReviews in Endocrine and Metabolic Disorders, 2016
- Coffee, tea and caffeine intake and the risk of non-melanoma skin cancer: a review of the literature and meta-analysisEuropean Journal of Nutrition, 2016
- Skin Cancer Epidemiology, Detection, and ManagementMedical Clinics of North America, 2015
- Human papillomaviruses: shared and distinct pathways for pathogenesisCurrent Opinion in Virology, 2015
- Anti-diabetic Drug Metformin: Challenges and Perspectives for Cancer TherapyCurrent Cancer Drug Targets, 2014
- Metformin Inhibits Skin Tumor Promotion in Overweight and Obese MiceCancer Prevention Research, 2014
- A systematic review of worldwide incidence of nonmelanoma skin cancerBritish Journal of Dermatology, 2012
- Cancer Trends in TaiwanJapanese Journal of Clinical Oncology, 2010
- Risk Factors for Histological Types and Anatomic Sites of Cutaneous Basal-Cell Carcinoma: An Italian Case–Control StudyJournal of Investigative Dermatology, 2007